دورية أكاديمية
أعرض في EDS

Prostate-Specific Membrane Antigen Use in Glioma Management: Past, Present, and Future.

التفاصيل البيبلوغرافية
العنوان: Prostate-Specific Membrane Antigen Use in Glioma Management: Past, Present, and Future.
المؤلفون: McBriar JD; From the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell., Shafiian N; From the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell., Scharf S; Departments of Nuclear Medicine., Boockvar JA; Neurosurgery., Wernicke AG; Radiation Medicine, Lenox Hill Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, NY.
المصدر: Clinical nuclear medicine [Clin Nucl Med] 2024 Jul 03. Date of Electronic Publication: 2024 Jul 03.
Publication Model: Ahead of Print
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Country of Publication: United States NLM ID: 7611109 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1536-0229 (Electronic) Linking ISSN: 03639762 NLM ISO Abbreviation: Clin Nucl Med Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Philadelphia, Lippincott.
مستخلص: Background: Prostate-specific membrane antigen (PSMA) is a membrane-bound metallopeptidase highly expressed in the neovasculature of many solid tumors including gliomas. It is a particularly enticing therapeutic target due to its ability to internalize, thereby delivering radioligands or pharmaceuticals to the intracellular compartment. Targeting the neovasculature of gliomas using PSMA for diagnosis and management has been a recent area of increased study and promise. The purpose of this review is to synthesize the current state and future directions of PSMA use in the histopathologic study, imaging, and treatment of gliomas.
Methods: PubMed and Scopus databases were used to conduct a literature review on PSMA use in gliomas in June 2023. Terms searched included "PSMA," "Prostate-Specific Membrane Antigen" OR "PSMA" OR "PSMA PET" AND "glioma" OR "high grade glioma" OR "glioblastoma" OR "GBM."
Results: Ninety-four publications were screened for relevance with 61 studies, case reports, and reviews being read to provide comprehensive context for the historical, contemporary, and prospective use of PSMA in glioma management.
Conclusions: PSMA PET imaging is currently a promising and accurate radiographic tool for the diagnosis and management of gliomas. PSMA histopathology likely represents a viable tool for helping predict glioma behavior. More studies are needed to investigate the role of PSMA-targeted therapeutics in glioma management, but preliminary reports have indicated its potential usefulness in treatment.
Competing Interests: Conflicts of interest and sources of funding: none declared.
(Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
References: Kiess AP, Banerjee SR, Mease RC, et al. Prostate-specific membrane antigen as a target for cancer imaging and therapy. Q J Nucl Med Mol Imaging. 2015;59:241–268.
Barinka C, Rojas C, Slusher B, et al. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem. 2012;19:856–870.
O’Keefe DS, Bacich DJ, Huang SS, et al. A perspective on the evolving story of PSMA biology, PSMA-based imaging, and endoradiotherapeutic strategies. J Nucl Med. 2018;59:1007–1013.
Miyahira AK, Soule HR. The history of prostate-specific membrane antigen as a theranostic target in prostate cancer: the cornerstone role of the Prostate Cancer Foundation. J Nucl Med. 2022;63:331–338.
de Galiza Barbosa F, Queiroz MA, Nunes RF, et al. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging. 2020;20:1–23.
Tan BF, Tan WCC, Wang FQ, et al. PSMA PET imaging and therapy in adenoid cystic carcinoma and other salivary gland cancers: a systematic review. Cancers (Basel). 2022;14:3585.
Verma P, Malhotra G, Goel A, et al. Differential uptake of 68Ga-PSMA-HBED-CC (PSMA-11) in low-grade versus high-grade gliomas in treatment-naive patients. Clin Nucl Med. 2019;44:e318–e322.
Wernicke AG, Edgar MA, Lavi E, et al. Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme. Arch Pathol Lab Med. 2011;135:1486–1489.
Liu H, Rajasekaran AK, Moy P, et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 1998;58:4055–4060.
Saffar H, Noohi M, Tavangar SM, et al. Expression of prostate-specific membrane antigen (PSMA) in brain glioma and its correlation with tumor grade. Iran J Pathol. 2018;13:45–53.
Šácha P, Zámečník J, Bařinka C, et al. Expression of glutamate carboxypeptidase II in human brain. Neuroscience. 2007;144:1361–1372.
Miller KD, Ostrom QT, Kruchko C, et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021;71:381–406.
Kumthekar P, Raizer J, Singh S. Low-grade glioma. Cancer Treat Res. 2015;75–87.
Nomura N, Pastorino S, Jiang P, et al. Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. Cancer Cell Int. 2014;14:26.
Mahzouni P, Shavakhi M. Prostate-specific membrane antigen expression in neovasculature of glioblastoma multiforme. Adv Biomed Res. 2019;8:18.
Oliveira D, Stegmayr C, Heinzel A, et al. High uptake of (68)Ga-PSMA and (18)F-DCFPyL in the peritumoral area of rat gliomas due to activated astrocytes. EJNMMI Res. 2020;10:55.
Holzgreve A, Biczok A, Ruf VC, et al. PSMA expression in glioblastoma as a basis for theranostic approaches: a retrospective, correlational panel study including immunohistochemistry, clinical parameters and PET imaging. Front Oncol. 2021;11:646387.
Traub-Weidinger T, Poetsch N, Woehrer A, et al. PSMA expression in 122 treatment naive glioma patients related to tumor metabolism in (11)C-methionine PET and survival. J Pers Med. 2021;11:624.
Coskun SK, Gamsizkan M, Yalcinkaya U, et al. STAT3, VEGF, and PSMA expression patterns in malignant peripheral nerve sheath tumors, malignant melanomas, and glioblastomas: does staining percentage and intensity have an effect on survival? J Environ Pathol Toxicol Oncol. 2022;41:45–53.
Tu W, Zheng H, Li L, et al. Secreted phosphoprotein 1 promotes angiogenesis of glioblastoma through upregulating PSMA expression via transcription factor HIF1α. Acta Biochim Biophys Sin (Shanghai). 2022;55:417–425.
Abdel Maguid MS, Saad El Dine MG, Gabal SM, et al. Prostate-specific membrane antigen (PSMA) expression in the neovasculature of high grade gliomas (histopathological and immunohistochemical study). Asian Pac J Cancer Prev. 2023;24:1797–1808.
Yuile A, Lee A, Moon EA, et al. PSMA expression correlates with improved overall survival and VEGF expression in glioblastoma. Biomedicine. 2023;11:1148.
Matsuda M, Ishikawa E, Yamamoto T, et al. Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with (89)Zr-Df-IAB2M anti-PSMA minibody. J Neurooncol. 2018;138:581–589.
Sasikumar A, Joy A, Pillai MR, et al. Diagnostic value of 68Ga PSMA-11 PET/CT imaging of brain tumors—preliminary analysis. Clin Nucl Med. 2017;42:e41–e48.
Sasikumar A, Kashyap R, Joy A, et al. Utility of 68G-PSMA-11 PET/CT in imaging of glioma—a pilot study. Clin Nucl Med. 2018;43:e304–e309.
Bertagna F, Albano D, Cerudelli E, et al. Potential of radiolabeled PSMA PET/CT or PET/MRI diagnostic procedures in gliomas/glioblastomas. Curr Radiopharm. 2020;13:94–98.
Akgun E, Akgun MY, Selcuk HH, et al. (68)Ga PSMA PET/MR in the differentiation of low and high grade gliomas: Is (68)Ga PSMA PET/MRI useful to detect brain gliomas? Eur J Radiol. 2020;130:109199.
Kunikowska J, Kulinski R, Muylle K, et al. 68Ga–prostate-specific membrane antigen-11 PET/CT: a new imaging option for recurrent glioblastoma multiforme? Clin Nucl Med. 2020;45:11–18.
Liu D, Cheng G, Ma X, et al. PET/CT using (68) Ga-PSMA-617 versus (18) F-fluorodeoxyglucose to differentiate low- and high-grade gliomas. J Neuroimaging. 2021;31:733–742.
Vallejo-Armenta P, Soto-Andonaegui J, Villanueva-Perez RM, et al. [(99m)Tc]Tc-iPSMA SPECT brain imaging as a potential specific diagnosis of metastatic brain tumors and high-grade gliomas. Nucl Med Biol. 2021;96–97:1–8.
Sahin M, Akgun E, Sirolu S, et al. Is there any additional benefit of (68)Ga-PSMA PET on radiotherapy target volume definition in patients with glioblastoma? Br J Radiol. 2022;95:20220049.
Truckenmueller P, Graef J, Scheel M, et al. [(68)Ga]Ga-PSMA PET/MRI, histological PSMA expression and preliminary experience with [(177)Lu]Lu-PSMA therapy in relapsing high-grade glioma. Front Oncol. 2022;12:980058.
Kumar A, ArunRaj ST, Bhullar K, et al. Ga-68 PSMA PET/CT in recurrent high-grade gliomas: evaluating PSMA expression in vivo. Neuroradiology. 2022;64:969–979.
Lavanya V, Malik IM, Nallapareddy K, et al. Correlation of target volumes on magnetic resonance imaging and prostate-specific membrane antigen brain scans in the treatment planning of glioblastomas. Indian J Nucl Med. 2022;37:245–248.
Muoio B, Albano D, Dondi F, et al. Diagnostic accuracy of PET/CT or PET/MRI using PSMA-targeting radiopharmaceuticals in high-grade gliomas: a systematic review and a bivariate meta-analysis. Diagnostics (Basel). 2022;12:1665.
Kunikowska J, Czepczynski R, Pawlak D, et al. Expression of glutamate carboxypeptidase II in the glial tumor recurrence evaluated in vivo using radionuclide imaging. Sci Rep. 2022;12:652.
Ninatti G, Pini C, Gelardi F, et al. The role of PET imaging in the differential diagnosis between radiation necrosis and recurrent disease in irradiated adult-type diffuse gliomas: a systematic review. Cancers (Basel). 2023;15:364.
Lindemann M, Oteiza A, Martin-Armas M, et al. Glioblastoma PET/MRI: kinetic investigation of [18F]rhPSMA-7.3, [18F]FET and [18F]fluciclovine in an orthotopic mouse model of cancer. Eur J Nucl Med Mol Imaging. 2023;50:1183–1194.
Moreau A, Khayi F, Maureille A, et al. Discriminating inflammatory radiation-related changes from early recurrence in patients with glioblastomas: a preliminary analysis of: 68Ga-PSMA-11 PET/CT compared with: 18F-FDOPA PET/CT. Clin Nucl Med. 2023;48:657–666.
Kunikowska J, Charzynska I, Kulinski R, et al. Tumor uptake in glioblastoma multiforme after IV injection of [(177)Lu]Lu-PSMA-617. Eur J Nucl Med Mol Imaging. 2020;47:1605–1606.
Kumar A, Ballal S, Yadav MP, et al. 177Lu-/68Ga-PSMA theranostics in recurrent glioblastoma multiforme: proof of concept. Clin Nucl Med. 2020;45:E512–E513.
More S, Naiker T, Jacobs N, et al. Short-interval, low-dose [177Lu]Lu–prostate-specific membrane antigen in the treatment of refractory glioblastoma. Clin Nucl Med. 2023;48:e217–e218.
Graef J, Bluemel S, Brenner W, et al. [(177)Lu]Lu-PSMA therapy as an individual treatment approach for patients with high-grade glioma: dosimetry results and critical statement. J Nucl Med. 2023;64:892–895.
Israeli RS, Powell CT, Fair WR, et al. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1993;53:227–230.
Muselaers S, Erdem S, Bertolo R, et al. PSMA PET/CT in renal cell carcinoma: an overview of current literature. J Clin Med. 2022;11:1829.
Bertagna F, Albano D, Cerudelli E, et al. Radiolabelled PSMA PET/CT in breast cancer. A systematic review. Nucl Med Rev Cent East Eur. 2020;23:32–35.
Vuijk FA, Kleiburg F, Noortman WA, et al. Prostate-specific membrane antigen targeted PET/CT imaging in patients with colon, gastric and pancreatic cancer. Cancers (Basel). 2022;14:6209.
Morris MJ, De Bono JS, Chi KN, et al. Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). American Society of Clinical Oncology. 2021:LBA4–LBA4.
Uijen M, Derks Y, Merkx R, et al. PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports. Eur J Nucl Med Mol Imaging. 2021;48:4350–4368.
Chang SS, Reuter VE, Heston W, et al. Five different anti–prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59:3192–3198.
Unterrainer M, Niyazi M, Ruf V, et al. The endothelial prostate-specific membrane antigen is highly expressed in gliosarcoma and visualized by [68Ga]-PSMA-11 PET: a theranostic outlook for brain tumor patients? Neuro Oncol. 2017;19:1698–1699.
Salas Fragomeni RA, Menke JR, Holdhoff M, et al. Prostate-specific membrane antigen–targeted imaging with [18F]DCFPyL in high-grade gliomas. Clin Nucl Med. 2017;42:e433–e435.
Salas Fragomeni RA, Pienta KJ, Pomper MG, et al. Uptake of prostate-specific membrane antigen–targeted 18F-DCFPyL in cerebral radionecrosis: implications for diagnostic imaging of high-grade gliomas. Clin Nucl Med. 2018;43:e419–e421.
Malik D, Kumar R, Mittal BR, et al. 68G-labeled PSMA uptake in nonprostatic malignancies: has the time come to remove “PS” from PSMA? Clin Nucl Med. 2018;43:529–532.
Kunikowska J, Bartosz K, Leszek K. Glioblastoma multiforme: another potential application for (68)Ga-PSMA PET/CT as a guide for targeted therapy. Eur J Nucl Med Mol Imaging. 2018;45:886–887.
Marafi F, Sasikumar A, Fathallah W, et al. 18F-PSMA 1007 brain PET/CT imaging in glioma recurrence. Clin Nucl Med. 2020;45:e61–e62.
Moreau A, Febvey O, Mognetti T, et al. Contribution of different positron emission tomography tracers in glioma management: focus on glioblastoma. Front Oncol. 2019;9:1134.
Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci. 2018;54:7–13.
Alifieris C, Trafalis DT. Glioblastoma multiforme: pathogenesis and treatment. Pharmacol Ther. 2015;152:63–82.
Pilati E, Nicolotti DG, Ceci F, et al. 68G–prostate-specific membrane antigen 11 PET/CT detects residual glioblastoma after radical surgery in a patient with synchronous recurrent prostate cancer: a case report. Clin Nucl Med. 2020;45:E151–E153.
Alongi P, Quartuccio N, Arnone A, et al. Brain PET/CT using prostate cancer radiopharmaceutical agents in the evaluation of gliomas. Clinical and Translational Imaging. 2020;8:433–448.
Cimini A, Ricci M, Russo F, et al. Peptide receptor radionuclide therapy and primary brain tumors: an overview. Pharmaceuticals (Basel). 2021;14:872.
Gupta M, Choudhury PS, Gairola M, et al. Pseudoprogression on 68Ga–prostate-specific membrane antigen-11 PET/CT in a treated glioblastoma. Clin Nucl Med. 2020;45:621–622.
Gupta M, Choudhury PS, Premsagar IC, et al. Role of 68Ga–prostate-specific membrane antigen PET/CT in disease assessment in glioblastoma within 48 hours of surgery. Clin Nucl Med. 2020;45:204–205.
Krebs S, Grommes C, McDevitt MR, et al. [(89)Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma. Eur J Nucl Med Mol Imaging. 2022;49:783–785.
Rizzo A, Dall'Armellina S, Pizzuto DA, et al. PSMA radioligand uptake as a biomarker of neoangiogenesis in solid tumours: diagnostic or theragnostic factor? Cancers (Basel). 2022;14:4039.
Stopa BM, Crowley J, Juhasz C, et al. Prostate-specific membrane antigen as target for neuroimaging of central nervous system tumors. Mol Imaging. 2022;2022:5358545.
Zhang X, Yuan J, Zhou C, et al. Diagnose of glioma using 68Ga-PSMA and 18F-FDG PET/MRI. Jpn J Clin Oncol. 2021;51:506–508.
Gao Y, Zheng H, Li L, et al. Prostate-specific membrane antigen (PSMA) promotes angiogenesis of glioblastoma through interacting with ITGB4 and regulating NF-κB signaling pathway. Front Cell Dev Biol. 2021;9:598377.
Kirchner MA, Holzgreve A, Brendel M, et al. PSMA PET imaging in glioblastoma: a preclinical evaluation and theranostic outlook. Front Oncol. 2021;11:774017.
Pernthaler B, Nazerani Hooshmand T, Igrec J, et al. Oligodendroglioma in 68Ga-PSMA-11 and 18F-fluciclovine PET/CT. Clin Nucl Med. 2021;46:e231–e232.
Jiang JY, Kang C, Bui P, et al. Incidental prostate-specific membrane antigen–avid glioblastoma detected on 68Ga–prostate-specific membrane antigen PET/CT. Radiol Case Rep. 2022;17:2023–2025.
Pirayesh E, Tavakoli M. Metachronous brain tumor in 177Lu-PSMA scan in a patient with metastatic castration resistant prostate cancer mimicking disease progression. Mol Imaging Radionucl Ther. 2023;32:54–56.
Moreau A, Marie E, Bonneville-Levard A, et al. Skull vault hemangioma mimicking neoplastic lesion on [68G]Ga-PSMA-11 PET/CT in a patient with glioblastoma: a case report. Radiol Case Rep. 2020;15:2598–2601.
Pełka K, Bodys-Pełka A, Kunikowska J. Prostate-specific membrane antigen expression in intracranial lesions—a review of the primary, metastatic, and nonneoplastic lesions. Nucl Med Rev Cent East Eur. 2023;26:134–142.
Chen Q, Lu L, Ma W. Efficacy, safety, and challenges of CAR T-cells in the treatment of solid tumors. Cancers (Basel). 2022;14:5983.
سلسلة جزيئية: ClinicalTrials.gov NCT05644080; NCT03903419; NCT04588454; NCT02410577
تواريخ الأحداث: Date Created: 20240705 Latest Revision: 20240705
رمز التحديث: 20240706
DOI: 10.1097/RLU.0000000000005365
PMID: 38968568
قاعدة البيانات: MEDLINE
الوصف
تدمد:1536-0229
DOI:10.1097/RLU.0000000000005365